Completed PHASE1 INTERVENTIONAL 7-arm NCT02443324

A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer

An Open-Label, Multicenter, Phase 1 Study of Ramucirumab Plus Pembrolizumab in Patients With Locally Advanced and Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Non-Small Cell Lung Cancer, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer

Sponsor: Eli Lilly and Company

Conditions Adenocarcinoma of the Gastroesophageal Junction Biliary Tract Cancer Carcinoma, Transitional Cell Gastric Adenocarcinoma Non-small Cell Lung Cancer

Interventions Pembrolizumab Ramucirumab

Updated 25 times since 2017 Last updated: Feb 19, 2024 Started: Jul 29, 2015 Primary completion: Aug 31, 2018 Completion: Apr 12, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Adenocarcinoma of the Gastroesophageal Junction and Biliary Tract Cancer, this trial is completed. The trial is conducted by Eli Lilly and Company and has accumulated 25 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

25 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Aug 2024 — Sep 2024 [monthly]

Completed PHASE1
Jul 2024 — Aug 2024 [monthly]

Completed PHASE1
Sep 2022 — Jul 2024 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed

▶ Show 20 earlier versions

Jun 2022 — Sep 2022 [monthly]

Active Not Recruiting PHASE1
Mar 2022 — Jun 2022 [monthly]

Active Not Recruiting PHASE1
Dec 2021 — Mar 2022 [monthly]

Active Not Recruiting PHASE1
May 2021 — Dec 2021 [monthly]

Active Not Recruiting PHASE1
Jan 2021 — May 2021 [monthly]

Active Not Recruiting PHASE1
Nov 2020 — Jan 2021 [monthly]

Active Not Recruiting PHASE1
Aug 2020 — Nov 2020 [monthly]

Active Not Recruiting PHASE1

Status: Completed → Active Not Recruiting
Jun 2020 — Aug 2020 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
Mar 2020 — Jun 2020 [monthly]

Active Not Recruiting PHASE1
Sep 2019 — Mar 2020 [monthly]

Active Not Recruiting PHASE1
Jan 2019 — Sep 2019 [monthly]

Active Not Recruiting PHASE1
Dec 2018 — Jan 2019 [monthly]

Active Not Recruiting PHASE1
Nov 2018 — Dec 2018 [monthly]

Active Not Recruiting PHASE1
Oct 2018 — Nov 2018 [monthly]

Active Not Recruiting PHASE1
Jun 2018 — Oct 2018 [monthly]

Active Not Recruiting PHASE1
Oct 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
Jul 2017 — Oct 2017 [monthly]

Recruiting PHASE1
May 2017 — Jul 2017 [monthly]

Recruiting PHASE1
Feb 2017 — May 2017 [monthly]

Recruiting PHASE1
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE1

First recorded

Jul 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eli Lilly and Company
Merck Sharp & Dohme LLC

Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Barcelona, Spain , Chattanooga, United States , Dijon, France , Dresden, Germany , Fort Myers, United States , Heidelberg, Germany , Kochi, Japan , Lille, France , London, United Kingdom , Lyon, France and 11 more locations